Webinar Scheduled for 2:30 PM PT/5:30 PM ET SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will discuss progress on its AlloCAR T platform during a virtual CD19 Forum on May 19, 2021 at 2:30 PM Pacific Time/5:30 PM Eastern Time. The Forum will include results from Phase 1 ALPHA (ALLO-501) and ALPHA2 (ALLO-501A) trials in relapsed/refractory non-Hodgkin lymphoma, developed in collaboration with Servier. The Company will also share safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from ALLO-647, a component of its differentiated lymphodepletion regimen. Allogene Presenters: David Chang, M.D., Ph.D. – President, Chief Executive Officer and Co-FounderRafael Amado, M.D. – Executive Vice President of Research & Development and Chief Medical OfficerEric Schmidt, Ph.D. – Chief Financial OfficerChristine Cassiano – Chief Communications Officer External Presenters: Frederick Locke, M.D. – Co-Leader of the Moffitt Immuno-Oncology Program and the Vice Chair and Associate Member of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at the Moffitt Cancer CenterMichael Tees, M.D., M.P.H. – Associate Member Physician, Colorado Blood Cancer Institute, Sarah Cannon Research InstituteLazaros Lekakis, M.D. – Associate Professor of Clinical Medicine, Transplantation and Cellular Therapy, Sylvester Cancer Center, University of Miami Poster presentations on data included in the Forum will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually June 4 – 8, 2021. WebinarPlease register for the webinar on the Company's website at www.allogene.com under the Investors tab in the News and Events section (https://ir.allogene.com/events) or by clicking the following link directly. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days. The materials presented will be available on the Allogene website. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and ability to present data, and the potential benefits of AlloCAR T™ therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended March 31, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. AlloCAR T™ is a trademark of Allogene Therapeutics, Inc. Allogene’s CD19 AlloCAR T program utilizes Cellectis technologies. ALLO-501 and ALLO-501A are being jointly developed under a collaboration agreement between Servier1 and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries. 1 Servier is an independent international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). Allogene Media/Investor Contact:Christine CassianoChief Communications Officer(714) 552-0326Christine.Cassiano@allogene.com
Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 47.92% and 56.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?